Eric James Mallack1,2, Keith P Van Haren3, Anna Torrey4, Stephanie van de Stadt5, Marc Engelen5, Gerald V Raymond6, Ali Fatemi7, Florian S Eichler8. 1. Department of Pediatrics, Division of Child Neurology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, USA ejm9009@med.cornell.edu. 2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Neurology, Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, CA, USA. 4. Department of Pediatrics, Division of Child Neurology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, USA. 5. Department of Pediatric Neurology, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, The Netherlands. 6. Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA. 7. The Moser Center for Leukodystrophies, Kennedy Krieger Institute, Johns Hopkins University, Baltimore, MD, USA. 8. Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND AND OBJECTIVES: We sought to characterize the natural history and standard of care practices between the radiologic appearance of brain lesions, the appearance of lesional enhancement, and treatment with hematopoietic stem cell transplant or gene therapy among boys diagnosed with presymptomatic childhood-onset cerebral adrenoleukodystrophy (CCALD). METHODS: We analyzed a multi-center, mixed retrospective/prospective cohort of patients diagnosed with presymptomatic CCALD (Neurologic Function Score [NFS] = 0, Loes Score [LS] = 0.5 - 9.0, Age < 13 years old). Two time-to-event survival analyses were conducted: (1) Time from CCALD lesion-onset-to-lesional enhancement, (2) Time from enhancement-to-treatment. The analysis was repeated in the subset of patients with (1) the earliest evidence of CCALD, defined as an MRI LS < 1, and (2) patients diagnosed between 2016 - 2021. RESULTS: Seventy-one boys were diagnosed with presymptomatic cerebral lesions at a median age of 6.4yo [2.4 - 12.1] with a LS of 1.5 [0.5 - 9.0]. Fifty percent of patients had lesional enhancement at diagnosis. In the remaining 50%, the median KM-estimate of time from diagnosis-to-lesional enhancement was 6.0 months [95%CI 3.6 - 17.8]. The median KM-estimate of time from enhancement-to-treatment is 3.8 months [95%CI 2.8 - 5.9]; two patients (4.2%) developed symptoms prior to treatment. Patients with a diagnostic LS < 1 were younger (5.8yo [2.4 - 11.5]), had a time-to-enhancement of 4.7mo [95%CI 2.7 - 9.30], and were treated in 3.8mo [95%CI 3.1 - 7.1]; no patients developed symptoms prior to treatment. Time from CCALD diagnosis-to-treatment decreased over the course of the study (ρ = -0.401, p = 0.003). CONCLUSION: Our findings offer a more refined understanding of the timing of lesion formation, enhancement, and treatment among boys with presymptomatic CCALD. These data offer benchmarks for standardizing clinical care and designing future clinical trials.
BACKGROUND AND OBJECTIVES: We sought to characterize the natural history and standard of care practices between the radiologic appearance of brain lesions, the appearance of lesional enhancement, and treatment with hematopoietic stem cell transplant or gene therapy among boys diagnosed with presymptomatic childhood-onset cerebral adrenoleukodystrophy (CCALD). METHODS: We analyzed a multi-center, mixed retrospective/prospective cohort of patients diagnosed with presymptomatic CCALD (Neurologic Function Score [NFS] = 0, Loes Score [LS] = 0.5 - 9.0, Age < 13 years old). Two time-to-event survival analyses were conducted: (1) Time from CCALD lesion-onset-to-lesional enhancement, (2) Time from enhancement-to-treatment. The analysis was repeated in the subset of patients with (1) the earliest evidence of CCALD, defined as an MRI LS < 1, and (2) patients diagnosed between 2016 - 2021. RESULTS: Seventy-one boys were diagnosed with presymptomatic cerebral lesions at a median age of 6.4yo [2.4 - 12.1] with a LS of 1.5 [0.5 - 9.0]. Fifty percent of patients had lesional enhancement at diagnosis. In the remaining 50%, the median KM-estimate of time from diagnosis-to-lesional enhancement was 6.0 months [95%CI 3.6 - 17.8]. The median KM-estimate of time from enhancement-to-treatment is 3.8 months [95%CI 2.8 - 5.9]; two patients (4.2%) developed symptoms prior to treatment. Patients with a diagnostic LS < 1 were younger (5.8yo [2.4 - 11.5]), had a time-to-enhancement of 4.7mo [95%CI 2.7 - 9.30], and were treated in 3.8mo [95%CI 3.1 - 7.1]; no patients developed symptoms prior to treatment. Time from CCALD diagnosis-to-treatment decreased over the course of the study (ρ = -0.401, p = 0.003). CONCLUSION: Our findings offer a more refined understanding of the timing of lesion formation, enhancement, and treatment among boys with presymptomatic CCALD. These data offer benchmarks for standardizing clinical care and designing future clinical trials.
Authors: Jieru E Lin; Eric A Armour; Arezou Heshmati; Christine Umandap; Julia J Couto; Alejandro D Iglesias; Eric J Mallack; Jennifer M Bain Journal: Neurology Date: 2019-07-09 Impact factor: 9.910
Authors: Hugo W Moser; Gerald V Raymond; Shou-En Lu; Larry R Muenz; Ann B Moser; Jiahong Xu; Richard O Jones; Daniel J Loes; Elias R Melhem; Prachi Dubey; Lena Bezman; N Hong Brereton; Augusto Odone Journal: Arch Neurol Date: 2005-07
Authors: Weston P Miller; Swetha Srinivasan; Angela Panoskaltsis-Mortari; Karnail Singh; Sharon Sen; Kelly Hamby; Taylor Deane; Linda Stempora; Jonathan Beus; Alexa Turner; Caleb Wheeler; Daniel C Anderson; Prachi Sharma; Anapatricia Garcia; Elizabeth Strobert; Eric Elder; Ian Crocker; Timothy Crenshaw; M Cecilia T Penedo; Thea Ward; Mingqing Song; John Horan; Christian P Larsen; Bruce R Blazar; Leslie S Kean Journal: Blood Date: 2010-09-10 Impact factor: 22.113
Authors: Elizabeth I Pierpont; Julie B Eisengart; Ryan Shanley; David Nascene; Gerald V Raymond; Elsa G Shapiro; Rich S Ziegler; Paul J Orchard; Weston P Miller Journal: JAMA Neurol Date: 2017-06-01 Impact factor: 18.302
Authors: Eric J Mallack; Stephanie van de Stadt; Paul A Caruso; Patricia L Musolino; Reza Sadjadi; Marc Engelen; Florian S Eichler Journal: Neurology Date: 2020-06-01 Impact factor: 9.910
Authors: Elizabeth I Pierpont; David R Nascene; Ryan Shanley; Daniel L Kenney-Jung; Richard S Ziegler; Weston P Miller; Ashish O Gupta; Troy C Lund; Paul J Orchard; Julie B Eisengart Journal: Neurology Date: 2020-07-02 Impact factor: 9.910